“Silicon isn’t just for computers. It can make a pretty good kidney, too” @WIRED#NephMadness 💪 contender in the #ArtificialKidney region
💥The device incorporated with silicon nanotechnology & tissue engineering - Let’s talk about The Implantable Bioartificial Kidney #NSMC
I have been drafting my dream AI-powered nephrology outpatient clinical workflow 🩺📈 and would love to share my thoughts 😊🤔
Discussion more on @ASNKidney AI forum
https://t.co/2L1KebEBny
As shown in the table, AI tools support each phase of the outpatient nephrology workflow:
Pre-visit, AI synthesizes EHR data 📋🤖 to highlight recent hospitalizations, medication changes, and abnormal labs. Risk models 🚩 prioritize high-acuity patients, while NLP triage identifies urgent referral reasons—ensuring a focused visit.
During the visit 🧑⚕️👩⚕️, ambient scribes and NLP tools 📝 reduce clerical burden, enhancing patient interaction. Decision-support systems integrate real-time data to guide evidence-based care 💊🧬, flag care gaps, and suggest personalized plans 📚✅.
Post-visit, AI monitors results and messages 📲🔁, triggering alerts for clinical deterioration. Home monitoring and AI inbox triage improve follow-up, reduce delays, and minimize unnecessary visits 🌐❤️🩹. @MayoClinicNeph
1/10
Last #NephJC we discussed the combination therapy of empagliflozin and finerenone 💊 #TenPostNephJC
🌵From a therapeutic dessert to a flood of options in DKD - what is the best timing to keep the kidneys afloat
DAPA-Tolvaptan: First trial of SGLT2 inhibition in ADPKD with background tolvaptan therapy @KIReports made it to the #TOM in this #ISNGTF May issue. See the latest #ISNGTF summary for details. VA by @md_abdulqader83
🧵1/10
📢 New Definition in Nephrology
Disease-Modifying Anti-Nephropathic Drugs (DMANDs) – A definition proposed by Immunonephrology Working Group (IWG) of the European Renal Association (ERA).
Why does this matter? Let’s break it down!
🔗 https://t.co/rz8ps0HIPY @NDTsocial
An @ERAkidney e-seminar by @ykoteng_LUMC moderators @willkidney and Dr Parminder Judge, panelist @AKronbichler
First in Novel CKD Treatments Beyond the Pillars (room K), Jonathan Barratt presenting
🥁Changes in proteinuria and kidney function in subgroups of patients with IgAN defined by baseline Gd-IgA1 levels in a Phase 1/2 study of zigakibart
Zigakibart= humanized MAb that blocks APRIL, a soluble factor whose blood level is elevated in patients with IgAN.
#era25 6/
💥 Game Changers in CKD and T2DM
💥 first up Peter Rossing on GLP1s
▶️Early CV studies suggested kidney benefits of GLP1s
▶️Flow trial designed to look at kidney outcomes in DKD
💥 Showed improvement in composite kidney outcomes, eGFR slope, cardiovascular outcomes and all cause mortality.
💥💥 NNT only 20 for composite kidney outcomes when treated for 3 years
💥 Outcomes similar if already on SGLT2 (15%)or on MRA ( 7%) -▶️ benefits additive!
💥More to come- tirzepatide also showing big effects and more trials on the way
💥💥Exciting times! 💥💥
- Sarah Gleeson
#ERA25#BeyondNephrology
1/And now one of the most awaited sessions in Late Breaking Clinical Trials 1: Cutting-Edge Clinical Trials in #Nephrology🥁
🚨 THE CONFIDENCE TRIAL: EFFICACY/SAFETY OF COMBINING FINERENONE WITH EMPAGLIFLOZIN IN PEOPLE WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES
👤Rajiv Agarwal
✖️@AgarwalRajivMD
👤 Peter Rossing
✖️@P_Rossing
👤 Hiddo J.L. Heerspink
✖️@HeerspinkHiddo
👤 Johannes F.E. Mann
Presented at #ERA25:
In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results: https://t.co/4Gf0LboOCp
@ERAkidney
@AINUKidneyRun
"Optimising prescription practises"
This #WorldKidneyDay AINU team promotes best prescription practises for optimal outcomes..
Creating awareness by annual running event..
✨ Embracing luminous traditions, the #TransplantConclave 🌟 begins with a vibrant inauguration.
Dr MV Rao sir gave inspiring opening remarks.
Program director @srikanthnephro addressed the distinguished audience
@ainuindia@ainunephrology
Hey #Nephpearls followers
#NephMadness 2️⃣🏀2️⃣3️⃣ is upon us‼️
LIKE ❤️ If this is the first time you’ve heard about it (if so, please click on link)
RETWEET 🔄 If you’re going to participate
Link 👉🏼 https://t.co/7LQc7TMBK1 via @AJKDonline